L04AC24 • mirikizumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors
Mirikizumabum is a monoclonal antibody used for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. It works by blocking interleukin-23 (IL-23), a protein involved in chronic inflammation, thereby reducing symptoms and promoting remission.
The medication is administered via subcutaneous injection or intravenous infusion, according to a specific regimen. It is effective in reducing inflammation and improving patients' quality of life.
Side effects may include upper respiratory tract infections, headache, fatigue, and injection site reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mirikizumabum. This medication must be administered under the supervision of a specialist.
Substance: mirikizumab
Date of last drug list: 01-09-2025
Commercial code: W71283001
Concentration: 100mg+200mg
Pharmaceutical form: solution for injection in pre-filled pen
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: LILLY FRANCE S.A.S. - FRANTA
Holder: ELI LILLY NEDERLAND B.V. - TARILE DE JOS
Number: 1736/2023/09
Shelf life: 2 years